Skip to main content
新芝生物 logo

新芝生物 — Investor Relations & Filings

Ticker · 920685 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2023-08-22 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920685

About 新芝生物

https://www.scientz.com/

Scientz Biotechnology specializes in the design and manufacture of high-performance life science instruments and laboratory equipment. The product range features ultrasonic cell disruptors, freeze dryers, gene guns, and high-pressure homogenizers, which are essential for sample preparation, cell lysis, and genetic engineering. The company also provides specialized solutions for tissue grinding, ultrasonic cleaning, and precise temperature control. These instruments serve a broad spectrum of applications in molecular biology, pharmaceutical research, environmental science, and agricultural technology. By integrating advanced ultrasonic and cryogenic technologies, Scientz supports research institutions and industrial laboratories in achieving accurate and reproducible results across various scientific disciplines.

Recent filings

Filing Released Lang Actions
独立董事关于第八届董事会第五次会议相关事项的事前认可意见和独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's eighth board meeting, including a special report on the use of raised funds and a proposal on establishing a controlling subsidiary and related party transactions. It contains independent opinions and approvals related to board meeting agenda items, referencing compliance with laws and company regulations. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is a board/management related announcement concerning board meeting matters and approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a full report or regulatory filing.
2023-08-22 Chinese
第八届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Ningbo New Zhi Biotechnology Co., Ltd. It details the meeting date, attendance, and the approval of several proposals including the review of the 2023 semi-annual report and related matters. The document references the actual 2023 semi-annual report and other detailed announcements published separately on the Beijing Stock Exchange information disclosure platform, indicating this document itself is not the full semi-annual report but a meeting resolution about it. The document length is short (1778 characters) and it serves as an official announcement of meeting decisions rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the interim report itself.
2023-08-22 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "宁波新芝生物科技股份有限公司 2023 年半年度报告" which translates to "Ningbo Scientz Biotechnology Co., Ltd. 2023 Semi-Annual Report." It contains detailed financial data such as revenue, profit, asset and liability figures, and operational performance for the period January 1, 2023 to June 30, 2023. The document includes sections on company overview, accounting data, business conditions, major events, share changes, management changes, and financial accounting reports. It explicitly states it is a half-year report (semi-annual report) and includes comprehensive financial statements and analysis. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
2023年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company Ningbo New Zhi Biotechnology Co., Ltd. It includes specifics on the amount raised, usage during the first half of 2023, balances, cash management activities, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and includes audit verification reports. It is a specialized report focused on the use of raised capital rather than a general financial report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document length is sufficient and contains substantive financial data related to fundraising and capital management, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-08-22 Chinese
对外投资设立控股子公司暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external investment to establish a controlling subsidiary and related party transactions. It details the investment overview, shareholder meeting approvals, investment purpose, risks, and the impact on the company. It does not contain financial statements or detailed financial performance data. The document is a formal announcement of a corporate action related to capital investment and related party transactions, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about the investment, not just a report publication announcement. Hence, CAP is the appropriate classification with high confidence.
2023-08-22 Chinese
关于召开 2023 年第二次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the company's 2023 second extraordinary general meeting of shareholders. It includes details about the meeting date, voting methods (including online voting), agenda items to be discussed (such as investment in a subsidiary), registration methods, and other procedural information. There is no financial data or report content, only an announcement of the meeting and its logistics. The document length is short (2438 characters), and it does not contain actual financial statements or detailed report content. Therefore, it is not an Annual Report, Interim Report, or any financial report. It is also not a voting result announcement, but a meeting notice. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual General Meeting or other shareholder meetings, including notices of meetings.
2023-08-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.